1. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The Curves study). Am J Cardiol 1998; 81: 582–7.

2. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25 % to 60 % in patients with primary hypercholesterolemia by atorvastatin a new HMS-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: 678–82.

3. Smith DG, Leslie SJ, Szucs TD, et al. Cost of treating to a modified European Atherosclerosis Society LDL6C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin. (Treatto-Target Study). Clin Drug Invest 1999; 17: 185–93.

4. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National cholesterol educational program goal versus “usual” care in secondary coronary heart disease prevention: The GREek Atorvastatin and Coronary-heartdisease Evaluation Study (GREACE). Cur Med Res Opin 2002; 18: 220–8.

5. Nissen S, Tuzcu M, Schoenhagen P. Effect of Intensive Compared With Moderate Lipid6Lowering Therapy on Progression of Coronary Atherosclerosis. JAMA 2004; 291: 1071–80.

6. Okazaki S, Yokoyama T, Miyauchi K Early Statin Treatment in Patients With Acute Coronary Syndrome. Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study. Circulation 2004; 110: 1061–8.

7. Nissen S, Nicholls S, Sipahi I. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTERIOD trial. JAMA 2006; 295: 1556–65.

8. Newman BC, Palmary G, Sielbershats H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trail in 9,416 patients. Am J Cardiol 2003; 92: 670–6.